TCF4 Is a Molecular Target of Resveratrol in the Prevention of Colorectal Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2015 May 12

PMID 25961950

Citations 18

Authors

Jin Boo Jeong

Jihye Lee

Seong-Ho Lee

Affiliations

Soon will be listed here.

Abstract

The Wnt/β-catenin pathway plays an essential role in the tumorigenesis of colorectal cancer. T-cell factor-4 (TCF4) is a member of the TCF/LEF (lymphoid enhancer factor) family of transcription factors, and dysregulation of β-catenin is decisive for the initiation and progression of colorectal cancer. However, the role of TCF4 in the transcriptional regulation of its target gene remained poorly understood. Resveratrol is a dietary phytoalexin and present in many plants, including grape skin, nuts and fruits. Although resveratrol has been widely implicated in anti-tumorigenic and pro-apoptotic properties in several cancer models, the underlying cellular mechanisms are only partially understood. The current study was performed to elucidate the molecular mechanism of the anti-cancer activity of resveratrol in human colorectal cancer cells. The treatment of resveratrol and other phytochemicals decreased the expression of TCF4. Resveratrol decreases cellular accumulation of exogenously-introduced TCF4 protein, but did not change the TCF4 transcription. The inhibition of proteasomal degradation using MG132 (carbobenzoxy-Leu-Leu-leucinal) and lactacystin ameliorates resveratrol-stimulated down-regulation of TCF4. The half-life of TCF4 was decreased in the cells exposed to resveratrol. Resveratrol increased phosphorylation of TCF4 at serine/threonine residues through ERK (extracellular signal-regulated kinases) and p38-dependent pathways. The TCF4 knockdown decreased TCF/β-catenin-mediated transcriptional activity and sensitized resveratrol-induced apoptosis. The current study provides a new mechanistic link between resveratrol and TCF4 down-regulation and significant benefits for further preclinical and clinical practice.

Citing Articles

Synergistic Mechanisms of Selected Polyphenols in Overcoming Chemoresistance and Enhancing Chemosensitivity in Colorectal Cancer.

Hon K, Naidu R Antioxidants (Basel). 2024; 13(7).

PMID: 39061884 PMC: 11273411. DOI: 10.3390/antiox13070815.

Hsa_circular RNA_0045474 Facilitates Osteoarthritis Via Modulating microRNA-485-3p and Augmenting Transcription Factor 4.

Zhang Z, Yu P, Bai L Mol Biotechnol. 2024; 66(5):1174-1187.

PMID: 38206529 DOI: 10.1007/s12033-023-01019-z.

Nonsense mutation suppression is enhanced by targeting different stages of the protein synthesis process.

Wittenstein A, Caspi M, Rippin I, Elroy-Stein O, Eldar-Finkelman H, Thoms S PLoS Biol. 2023; 21(11):e3002355.

PMID: 37943958 PMC: 10684085. DOI: 10.1371/journal.pbio.3002355.

Review Deciphering the Anticancer Efficacy of Resveratrol and their Associated Mechanisms in Human Carcinoma.

Arif M, Pandey P, Khan F Endocr Metab Immune Disord Drug Targets. 2023; 24(9):1015-1026.

PMID: 37929735 DOI: 10.2174/0118715303251351231018145903.

β-catenin inhibitors in cancer therapeutics: intricacies and way forward.

Dev Jr A, Vachher M, Prasad C Bioengineered. 2023; 14(1):2251696.

PMID: 37655825 PMC: 10478749. DOI: 10.1080/21655979.2023.2251696.

References

She Q, Bode A, Ma W, Chen N, Dong Z . Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res. 2001; 61(4):1604-10. View

Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L . Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway. PLoS One. 2013; 8(11):e78700. PMC: 3823921. DOI: 10.1371/journal.pone.0078700. View

van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A . The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002; 111(2):241-50. DOI: 10.1016/s0092-8674(02)01014-0. View

Ishitani T, Ninomiya-Tsuji J, Matsumoto K . Regulation of lymphoid enhancer factor 1/T-cell factor by mitogen-activated protein kinase-related Nemo-like kinase-dependent phosphorylation in Wnt/beta-catenin signaling. Mol Cell Biol. 2003; 23(4):1379-89. PMC: 141159. DOI: 10.1128/MCB.23.4.1379-1389.2003. View

Yamamoto H, Ihara M, Matsuura Y, Kikuchi A . Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J. 2003; 22(9):2047-59. PMC: 156076. DOI: 10.1093/emboj/cdg204. View

Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M . Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene. 2004; 23(19):3376-84. DOI: 10.1038/sj.onc.1207464. View

Bos J, Fearon E, Hamilton S, Verlaan-de Vries M, VAN Boom J, Van Der Eb A . Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987; 327(6120):293-7. DOI: 10.1038/327293a0. View

Fearon E, Hamilton S, Vogelstein B . Clonal analysis of human colorectal tumors. Science. 1987; 238(4824):193-7. DOI: 10.1126/science.2889267. View

Behrens J, von Kries J, Kuhl M, Bruhn L, Wedlich D, Grosschedl R . Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996; 382(6592):638-42. DOI: 10.1038/382638a0. View

10.

Korinek V, Barker N, Morin P, van Wichen D, de Weger R, Kinzler K . Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997; 275(5307):1784-7. DOI: 10.1126/science.275.5307.1784. View

11.

Morin P, Sparks A, Korinek V, Barker N, Clevers H, Vogelstein B . Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275(5307):1787-90. DOI: 10.1126/science.275.5307.1787. View

12.

Tetsu O, McCormick F . Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 1999; 398(6726):422-6. DOI: 10.1038/18884. View

13.

Ihara M, Yamamoto H, Kikuchi A . SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol Cell Biol. 2005; 25(9):3506-18. PMC: 1084305. DOI: 10.1128/MCB.25.9.3506-3518.2005. View

14.

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh J, Comber H . Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49(6):1374-403. DOI: 10.1016/j.ejca.2012.12.027. View

15.

Jeong J, Yang X, Clark R, Choi J, Baek S, Lee S . A mechanistic study of the proapoptotic effect of tolfenamic acid: involvement of NF-κB activation. Carcinogenesis. 2013; 34(10):2350-60. DOI: 10.1093/carcin/bgt224. View

16.

Fouad M, Agha A, Merzabani M, Shouman S . Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol. 2013; 32(10):1067-80. DOI: 10.1177/0960327113475679. View

17.

Fodde R, Smits R, Clevers H . APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2002; 1(1):55-67. DOI: 10.1038/35094067. View

18.

Kundu J, Choi K, Surh Y . beta-Catenin-mediated signaling: a novel molecular target for chemoprevention with anti-inflammatory substances. Biochim Biophys Acta. 2005; 1765(1):14-24. DOI: 10.1016/j.bbcan.2005.08.006. View

19.

Trincheri N, Nicotra G, Follo C, Castino R, Isidoro C . Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis. 2006; 28(5):922-31. DOI: 10.1093/carcin/bgl223. View

20.

Das S, Das D . Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets. 2007; 6(3):168-73. DOI: 10.2174/187152807781696464. View